ROIV Stock Summary and Trading Ideas (Roivant Sciences Ltd. - Common Shares | NASDAQ:ROIV)

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.

As of April 3, 2025, ROIV stock price declined to $10.01 with 9,871,799 million shares trading.

ROIV has a beta of 0.81, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.14 to the broad based SPY ETF.

ROIV has a market cap of $7.14 billion. This is considered a Mid Cap stock.

Last quarter Roivant Sciences Ltd. - Common Shares reported $9 million in Revenue and -$.20 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.04.

In the last 3 years, ROIV traded as high as $13.24 and as low as $2.52.

The top ETF exchange traded funds that ROIV belongs to (by Net Assets): VTI, IJH, VB, VBK, VXF.

ROIV has underperformed the market in the last year with a price return of -8.3% while the SPY ETF gained +4.8%. ROIV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.1% and -8.5%, respectively, while the SPY returned -7.9% and -5.1%, respectively.

ROIV support price is $9.87 and resistance is $10.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.